|
|
|
| home > ebr > Winter 2004 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Tayton-Martin introduces the topics for this issue |
|
|
|
|
| We understand much about the process of ageing, but Can Biotech Turn Back the Clock? G Steven Burrill, CEO of Burrill & Company, considers the possibilities |
|
|
| Dr M Evelyn Rose, Associate Director, eCommunications at CV Therapeutics, explores an emerging therapeutic avenue to fight the primary cause of death worldwide, in Small Molecule Therapies: Innovative Strategies for the Management of Cardiovascular Disease |
|
|
| Getting to grips with Genetic Testing - The Prospect for Progress in Type 2 Diabetes - David Brady, Vice President of Business Development at Integragen, asks how prediction of susceptibility might combat the explosive increase in sufferers |
|
|
| In both clinical and commercial terms, the advantages of Oral Insulin Therapy are manifold, asserts Dr Roger New, Executive Director of Proxima Concepts Ltd |
|
|
| In Potential Mass Scale Genotyping of Human Blood Groups in Europe, by Neil D Avent, Professor and Research Director at the Centre for Research in Biomedicine and Genomics Research Institute, discusses the current and future uses of this technique for predicting disease |
|
|
| The potential of pharmacogenetic profiling is explored in Personalised Medicine - Recognising the Link Between an Individual's Genetics and their Response to Drugs, by Dr CA. Dale Smith, Managing Director at GenoVar Bioscience, and Dr Paul G Debenham, Director of Life Sciences at LGC |
|
|
|
| Reviewing risks, rewards and evolving business practice, in Trends in Biopharma Deal-Making, by Heather Cartwright, Business Analyst at PharmaVentures |
|
|
| Dr Hubert Birner, General Partner at Techno Venture Management, underlines the need for an innovative approach to deal-making, in Co-Exclusive Licensing: The Best of Both Worlds |
|
|
| In Economic Development - Bridging the Early-Stage Funding Gap in European Life Sciences, Dr Michael Bayewitch, Director of Programme Co-ordination, Dr Jeremy Quirk, Market Analyst, and Dr John Chiplin, CEO of ITI Life Sciences, examine initiatives that develop sustained financial support |
|
|
|
| Trade marks are essential to the longevity of a brand - Laurel McBray, Partner at Withers & Rogers, asks Is There Life After Patents? |
|
|
| Catherine Narayan-Dubois, Regulatory Affairs Officer at Chiltern International, discusses the implications of this year's new legislation, in Entering the Era of the EU Clinical Trials Directive |
|
|
|
| In Reducing Risk in Biopharmaceutical Production by Controlling Glycosylation, Dr Daryl Fernandes, Founder and CEO of Ludger Ltd, provides a systematic approach to minimising the risks associated with this aspect of glycoprotein therapeutics |
|
|
| Dr Barbara Collins, Director of Global Product Development at PRA International, cautions that an awareness of 'chemo fog' is crucial, in Cognitive Effects of Chemotherapy: Implications for the Evaluation of New Cytotoxic Drugs |
|
|
| Get a perspective on the investigation of biological questions from Dr Martin Seifert, DNA Microarray Specialist, and Dr Matthias Scherf, Head of Discovery at Genomatix Software GmbH, in Biology Centred Microarray Analysis - From Co-Expression to Co-Regulation |
|
|
| In Human Stem Cell Lines: The Role of Cell Banks in Assuring Quality for Research and Clinical Development in Cell Therapy, Professor Glyn Stacey, Head of Division of Cell Biology and Imaging, Director of the UK Stem Cell Bank and Professor of Cryobiology at the University of Luton, National Institute for Biological Standards and Control, addresses the issues involved in managing stem cells |
|
|
|
| In Informatics from Data Analysis to Data Association - Understanding the Relevance of -Omics Data, Dr Licen Xu, Informatics Product Manager, Integrated Biology Solutions at Agilent Technologies Inc, explains how to make the most of scientific findings via the latest tools available |
|
|
| How can we get information more reliably, quickly, and for less resources and money, into drug discovery and development? Peter May, Managing Director (Europe) at NovaScreen Biosciences and Managing Director of May Analytic Consulting, presents useful Business Strategies: Challenges and Opportunities in Moving to Microfluidics |
|
|
| Dr Wayne Bowen, Chief Scientific Officer, and Dr Matthew Cook, Development Scientist at TTP Labtech, explore recent developments in lead discovery, in Technologies to Enable High Content Analysis |
|
|
| Dr Sue Cooke, Product Manager for Proteomics and Cell Analysis, and Dr Sean Donnelly, Technical Services Manager at Promega, consider solutions to the challenge of assay selection, in Cell-Based Assays - Choosing the Right One to Reach your Research Goals |
|
|
|
| An overview of the BEP Challenge in The UK Champions Exploitation of Biotechnology, by Lord Sainsbury, Minister for Science and Innovation at the UK Department of Trade and Industry (DTI)An overview of the BEP Challenge in The UK Champions Exploitation of Biotechnology, by Lord Sainsbury, Minister for Science and Innovation at the UK Department of Trade and Industry (DTI) |
|
|
| Dr Jeff Solomon, Chief Executive of ERBI, discusses the formation and growth of a biotech cluster, in Biotechnology in Cambridge, UK - The Low Risk Location for a High Risk Industry |
|
|
|
| MaRS Attracts! Dr Adam Stoten, Head of Research at Technomark investigates an exciting development in Canadian biotech |
|
|
| Mark Wilson, Senior Development Leader, and Stephen Squirrell, Quality Manager at Xenova, present a practical guide to adapting to changing standards and expectations, in The Impact of the EU Clinical Trials Directive on Biologics Manufacture |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Avacta announces license agreement with POINT Biopharma Inc.
Cambridge and Wetherby, UK, 07 January 2021: Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc. (“POINT”), to provide access to Avacta’s pre|CISION technology for the development of tumour-activated radiopharmaceuticals.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Getting the Client’s Trust - Oncology Program
Cmed Clinical Services
Five years ago, a biopharmaceutical company chose Cmed to conduct a
phase II oncology study. Cmed’s performance of the study and the good
relationship established with the Client led Cmed to be awarded a second
oncology trial which a couple of years ago was followed by a third,
fourth and fifth.
More info >> |
|
|
.jpg)
